百濟神州(06160.HK)「百澤安」聯合化療一線晚期或轉移性食管鱗狀細胞癌中總生存期中位17.2個月
百濟神州(06160.HK)公布全球三期臨床試驗RATIONALE 306的最新數據,評估「百澤安」聯合化療治療既往未接受過晚期疾病全身治療的晚期或轉移性食管鱗狀細胞癌(ESCC)成人患者的效果。
在今年歐洲腫瘤內科學會(ESMO)世界胃腸癌大會上,公司口頭報告是次研究的最新數據結果,顯示接受「百澤安」聯合化療的患者總生存期(OS)取得統計學顯著性和臨床意義的改善,中位OS為17.2個月,而接受安慰劑聯合化療的患者的中位OS為10.6個月。與安慰劑聯合化療相比,「百澤安」聯合化療使患者死亡風險降低34%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.